Vascular endothelial growth factor 8610

Background Angiogenesis is a key element in solid-tumor growth, invasion, and metastasis. VEGF is among the most potent angiogenic factor thus far detected. The aim of the present study is to explore the potential of VEGF (also known as VEGF-A) as a prognostic and predictive biomarker among men with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Radiation oncology (London, England) England), 2013-04, Vol.8
Hauptverfasser: Pan, Larry, Baek, Seunghee, Edmonds, Pamela R, Roach, Mack, Wolkov, Harvey, Shah, Satish, Pollack, Alan, Hammond, M Elizabeth, Dicker, Adam P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Radiation oncology (London, England)
container_volume 8
creator Pan, Larry
Baek, Seunghee
Edmonds, Pamela R
Roach, Mack
Wolkov, Harvey
Shah, Satish
Pollack, Alan
Hammond, M Elizabeth
Dicker, Adam P
description Background Angiogenesis is a key element in solid-tumor growth, invasion, and metastasis. VEGF is among the most potent angiogenic factor thus far detected. The aim of the present study is to explore the potential of VEGF (also known as VEGF-A) as a prognostic and predictive biomarker among men with locally advanced prostate cancer. Methods The analysis was performed using patients enrolled on RTOG 8610, a phase III randomized control trial of radiation therapy alone (Arm 1) versus short-term neoadjuvant and concurrent androgen deprivation and radiation therapy (Arm 2) in men with locally advanced prostate carcinoma. Tissue samples were obtained from the RTOG tissue repository. Hematoxylin and eosin slides were reviewed, and paraffin blocks were immunohistochemically stained for VEGF expression and graded by Intensity score (0-3). Cox or Fine and Gray's proportional hazards models were used. Results Sufficient pathologic material was available from 103 (23%) of the 456 analyzable patients enrolled in the RTOG 8610 study. There were no statistically significant differences in the pre-treatment characteristics between the patient groups with and without VEGF intensity data. Median follow-up for all surviving patients with VEGF intensity data is 12.2 years. Univariate and multivariate analyses demonstrated no statistically significant correlation between the intensity of VEGF expression and overall survival, distant metastasis, local progression, disease-free survival, or biochemical failure. VEGF expression was also not statistically significantly associated with any of the endpoints when analyzed by treatment arm. Conclusions This study revealed no statistically significant prognostic or predictive value of VEGF expression for locally advanced prostate cancer. This analysis is among one of the largest sample bases with long-term follow-up in a well-characterized patient population. There is an urgent need to establish multidisciplinary initiatives for coordinating further research in the area of human prostate cancer biomarkers. Keywords: Prostate cancer, Vascular endothelial growth factor, Prognostic biomarker, Predictive biomarker, Radiation therapy
doi_str_mv 10.1186/1748-717X-8-100
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A534715412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534715412</galeid><sourcerecordid>A534715412</sourcerecordid><originalsourceid>FETCH-LOGICAL-g672-44318d54419095e5b2e6ab973891575ea15bec6b5a351ba5cbc6036311927ee73</originalsourceid><addsrcrecordid>eNptjM1Lw0AUxBdRsFbPXgMePG3dl923H8dStAqFXkrxVt5uXtJImkAS8d83oEgPMocZfsyMEPegFgDePoEzXjpw79JLUOpCzP7I5Vm-FjfD8KGUQa3CTDzuaUifDfUZt0U3Hrmpqcmqvvsaj1lJaez6zFtQt-KqpGbgu1-fi93L8271Kjfb9dtquZGVdbk0RoMv0BgIKiBjzNlSDE77AOiQCTByshFJI0TCFJNV2mqAkDtmp-fi4ee2ooYPdVt2Y0_pVA_psERtHKCBfGot_mlNKvhUp67lsp742eAbnTdPnw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Vascular endothelial growth factor 8610</title><source>DOAJ Directory of Open Access Journals</source><source>SpringerNature Journals</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Pan, Larry ; Baek, Seunghee ; Edmonds, Pamela R ; Roach, Mack ; Wolkov, Harvey ; Shah, Satish ; Pollack, Alan ; Hammond, M Elizabeth ; Dicker, Adam P</creator><creatorcontrib>Pan, Larry ; Baek, Seunghee ; Edmonds, Pamela R ; Roach, Mack ; Wolkov, Harvey ; Shah, Satish ; Pollack, Alan ; Hammond, M Elizabeth ; Dicker, Adam P</creatorcontrib><description>Background Angiogenesis is a key element in solid-tumor growth, invasion, and metastasis. VEGF is among the most potent angiogenic factor thus far detected. The aim of the present study is to explore the potential of VEGF (also known as VEGF-A) as a prognostic and predictive biomarker among men with locally advanced prostate cancer. Methods The analysis was performed using patients enrolled on RTOG 8610, a phase III randomized control trial of radiation therapy alone (Arm 1) versus short-term neoadjuvant and concurrent androgen deprivation and radiation therapy (Arm 2) in men with locally advanced prostate carcinoma. Tissue samples were obtained from the RTOG tissue repository. Hematoxylin and eosin slides were reviewed, and paraffin blocks were immunohistochemically stained for VEGF expression and graded by Intensity score (0-3). Cox or Fine and Gray's proportional hazards models were used. Results Sufficient pathologic material was available from 103 (23%) of the 456 analyzable patients enrolled in the RTOG 8610 study. There were no statistically significant differences in the pre-treatment characteristics between the patient groups with and without VEGF intensity data. Median follow-up for all surviving patients with VEGF intensity data is 12.2 years. Univariate and multivariate analyses demonstrated no statistically significant correlation between the intensity of VEGF expression and overall survival, distant metastasis, local progression, disease-free survival, or biochemical failure. VEGF expression was also not statistically significantly associated with any of the endpoints when analyzed by treatment arm. Conclusions This study revealed no statistically significant prognostic or predictive value of VEGF expression for locally advanced prostate cancer. This analysis is among one of the largest sample bases with long-term follow-up in a well-characterized patient population. There is an urgent need to establish multidisciplinary initiatives for coordinating further research in the area of human prostate cancer biomarkers. Keywords: Prostate cancer, Vascular endothelial growth factor, Prognostic biomarker, Predictive biomarker, Radiation therapy</description><identifier>ISSN: 1748-717X</identifier><identifier>EISSN: 1748-717X</identifier><identifier>DOI: 10.1186/1748-717X-8-100</identifier><language>eng</language><publisher>BioMed Central Ltd</publisher><subject>Analysis ; Care and treatment ; Gene expression ; Health aspects ; Medical research ; Medicine, Experimental ; Metastasis ; Physiological aspects ; Prostate cancer ; Radiation ; Radiotherapy ; Vascular endothelial growth factor</subject><ispartof>Radiation oncology (London, England), 2013-04, Vol.8</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Pan, Larry</creatorcontrib><creatorcontrib>Baek, Seunghee</creatorcontrib><creatorcontrib>Edmonds, Pamela R</creatorcontrib><creatorcontrib>Roach, Mack</creatorcontrib><creatorcontrib>Wolkov, Harvey</creatorcontrib><creatorcontrib>Shah, Satish</creatorcontrib><creatorcontrib>Pollack, Alan</creatorcontrib><creatorcontrib>Hammond, M Elizabeth</creatorcontrib><creatorcontrib>Dicker, Adam P</creatorcontrib><title>Vascular endothelial growth factor 8610</title><title>Radiation oncology (London, England)</title><description>Background Angiogenesis is a key element in solid-tumor growth, invasion, and metastasis. VEGF is among the most potent angiogenic factor thus far detected. The aim of the present study is to explore the potential of VEGF (also known as VEGF-A) as a prognostic and predictive biomarker among men with locally advanced prostate cancer. Methods The analysis was performed using patients enrolled on RTOG 8610, a phase III randomized control trial of radiation therapy alone (Arm 1) versus short-term neoadjuvant and concurrent androgen deprivation and radiation therapy (Arm 2) in men with locally advanced prostate carcinoma. Tissue samples were obtained from the RTOG tissue repository. Hematoxylin and eosin slides were reviewed, and paraffin blocks were immunohistochemically stained for VEGF expression and graded by Intensity score (0-3). Cox or Fine and Gray's proportional hazards models were used. Results Sufficient pathologic material was available from 103 (23%) of the 456 analyzable patients enrolled in the RTOG 8610 study. There were no statistically significant differences in the pre-treatment characteristics between the patient groups with and without VEGF intensity data. Median follow-up for all surviving patients with VEGF intensity data is 12.2 years. Univariate and multivariate analyses demonstrated no statistically significant correlation between the intensity of VEGF expression and overall survival, distant metastasis, local progression, disease-free survival, or biochemical failure. VEGF expression was also not statistically significantly associated with any of the endpoints when analyzed by treatment arm. Conclusions This study revealed no statistically significant prognostic or predictive value of VEGF expression for locally advanced prostate cancer. This analysis is among one of the largest sample bases with long-term follow-up in a well-characterized patient population. There is an urgent need to establish multidisciplinary initiatives for coordinating further research in the area of human prostate cancer biomarkers. Keywords: Prostate cancer, Vascular endothelial growth factor, Prognostic biomarker, Predictive biomarker, Radiation therapy</description><subject>Analysis</subject><subject>Care and treatment</subject><subject>Gene expression</subject><subject>Health aspects</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Metastasis</subject><subject>Physiological aspects</subject><subject>Prostate cancer</subject><subject>Radiation</subject><subject>Radiotherapy</subject><subject>Vascular endothelial growth factor</subject><issn>1748-717X</issn><issn>1748-717X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptjM1Lw0AUxBdRsFbPXgMePG3dl923H8dStAqFXkrxVt5uXtJImkAS8d83oEgPMocZfsyMEPegFgDePoEzXjpw79JLUOpCzP7I5Vm-FjfD8KGUQa3CTDzuaUifDfUZt0U3Hrmpqcmqvvsaj1lJaez6zFtQt-KqpGbgu1-fi93L8271Kjfb9dtquZGVdbk0RoMv0BgIKiBjzNlSDE77AOiQCTByshFJI0TCFJNV2mqAkDtmp-fi4ee2ooYPdVt2Y0_pVA_psERtHKCBfGot_mlNKvhUp67lsp742eAbnTdPnw</recordid><startdate>20130425</startdate><enddate>20130425</enddate><creator>Pan, Larry</creator><creator>Baek, Seunghee</creator><creator>Edmonds, Pamela R</creator><creator>Roach, Mack</creator><creator>Wolkov, Harvey</creator><creator>Shah, Satish</creator><creator>Pollack, Alan</creator><creator>Hammond, M Elizabeth</creator><creator>Dicker, Adam P</creator><general>BioMed Central Ltd</general><scope/></search><sort><creationdate>20130425</creationdate><title>Vascular endothelial growth factor 8610</title><author>Pan, Larry ; Baek, Seunghee ; Edmonds, Pamela R ; Roach, Mack ; Wolkov, Harvey ; Shah, Satish ; Pollack, Alan ; Hammond, M Elizabeth ; Dicker, Adam P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g672-44318d54419095e5b2e6ab973891575ea15bec6b5a351ba5cbc6036311927ee73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Analysis</topic><topic>Care and treatment</topic><topic>Gene expression</topic><topic>Health aspects</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Metastasis</topic><topic>Physiological aspects</topic><topic>Prostate cancer</topic><topic>Radiation</topic><topic>Radiotherapy</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pan, Larry</creatorcontrib><creatorcontrib>Baek, Seunghee</creatorcontrib><creatorcontrib>Edmonds, Pamela R</creatorcontrib><creatorcontrib>Roach, Mack</creatorcontrib><creatorcontrib>Wolkov, Harvey</creatorcontrib><creatorcontrib>Shah, Satish</creatorcontrib><creatorcontrib>Pollack, Alan</creatorcontrib><creatorcontrib>Hammond, M Elizabeth</creatorcontrib><creatorcontrib>Dicker, Adam P</creatorcontrib><jtitle>Radiation oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pan, Larry</au><au>Baek, Seunghee</au><au>Edmonds, Pamela R</au><au>Roach, Mack</au><au>Wolkov, Harvey</au><au>Shah, Satish</au><au>Pollack, Alan</au><au>Hammond, M Elizabeth</au><au>Dicker, Adam P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vascular endothelial growth factor 8610</atitle><jtitle>Radiation oncology (London, England)</jtitle><date>2013-04-25</date><risdate>2013</risdate><volume>8</volume><issn>1748-717X</issn><eissn>1748-717X</eissn><abstract>Background Angiogenesis is a key element in solid-tumor growth, invasion, and metastasis. VEGF is among the most potent angiogenic factor thus far detected. The aim of the present study is to explore the potential of VEGF (also known as VEGF-A) as a prognostic and predictive biomarker among men with locally advanced prostate cancer. Methods The analysis was performed using patients enrolled on RTOG 8610, a phase III randomized control trial of radiation therapy alone (Arm 1) versus short-term neoadjuvant and concurrent androgen deprivation and radiation therapy (Arm 2) in men with locally advanced prostate carcinoma. Tissue samples were obtained from the RTOG tissue repository. Hematoxylin and eosin slides were reviewed, and paraffin blocks were immunohistochemically stained for VEGF expression and graded by Intensity score (0-3). Cox or Fine and Gray's proportional hazards models were used. Results Sufficient pathologic material was available from 103 (23%) of the 456 analyzable patients enrolled in the RTOG 8610 study. There were no statistically significant differences in the pre-treatment characteristics between the patient groups with and without VEGF intensity data. Median follow-up for all surviving patients with VEGF intensity data is 12.2 years. Univariate and multivariate analyses demonstrated no statistically significant correlation between the intensity of VEGF expression and overall survival, distant metastasis, local progression, disease-free survival, or biochemical failure. VEGF expression was also not statistically significantly associated with any of the endpoints when analyzed by treatment arm. Conclusions This study revealed no statistically significant prognostic or predictive value of VEGF expression for locally advanced prostate cancer. This analysis is among one of the largest sample bases with long-term follow-up in a well-characterized patient population. There is an urgent need to establish multidisciplinary initiatives for coordinating further research in the area of human prostate cancer biomarkers. Keywords: Prostate cancer, Vascular endothelial growth factor, Prognostic biomarker, Predictive biomarker, Radiation therapy</abstract><pub>BioMed Central Ltd</pub><doi>10.1186/1748-717X-8-100</doi></addata></record>
fulltext fulltext
identifier ISSN: 1748-717X
ispartof Radiation oncology (London, England), 2013-04, Vol.8
issn 1748-717X
1748-717X
language eng
recordid cdi_gale_infotracmisc_A534715412
source DOAJ Directory of Open Access Journals; SpringerNature Journals; PubMed Central Open Access; Springer Nature OA Free Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Analysis
Care and treatment
Gene expression
Health aspects
Medical research
Medicine, Experimental
Metastasis
Physiological aspects
Prostate cancer
Radiation
Radiotherapy
Vascular endothelial growth factor
title Vascular endothelial growth factor 8610
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A46%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vascular%20endothelial%20growth%20factor%208610&rft.jtitle=Radiation%20oncology%20(London,%20England)&rft.au=Pan,%20Larry&rft.date=2013-04-25&rft.volume=8&rft.issn=1748-717X&rft.eissn=1748-717X&rft_id=info:doi/10.1186/1748-717X-8-100&rft_dat=%3Cgale%3EA534715412%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A534715412&rfr_iscdi=true